Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Emisphere Technologies, Inc. (OTC: EMIS).

Full DD Report for EMIS

You must become a subscriber to view this report.

Recent News from (OTC: EMIS)

Emisphere's Proprietary Eligen Technology Supports Novo Nordisk's Oral Semaglutide
ROSELAND, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- On August 20, 2018, Novo Nordisk A/S (Novo Nordisk) announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults with type 2 diabetes and moderate renal impairment. A copy of Novo Nordisk's announcement can...
Source: GlobeNewswire
Date: August, 28 2018 16:05
ELIGEN B12 Receives "Amazon's Choice" Designation
ROSELAND, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that its non-prescription medical food product, Eligen B12, has earned the coveted “Amazon’s Choice” designation for being highly rated, fairly-priced, and av...
Source: GlobeNewswire
Date: May, 30 2018 08:45
Emisphere's Solid Future
If you read my last two articles about Emisphere Technologies ( OTCPK:EMIS ) and acted on them, you could be up as much as 2-3x on your investment. It turns out that some near-term news did seem to push the stock up. EMIS is a small-cap biotech/pharmaceutical company that recently went d...
Source: SeekingAlpha
Date: May, 08 2018 07:41
Emisphere Amends License Agreement with Novo Nordisk
ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the development and commercialization of oral formulations...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Emisphere Development Update
ROSELAND, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emispher...
Source: GlobeNewswire
Date: February, 22 2018 16:18
Emisphere: Near-Term News May Push The Price Back Up
Emisphere ( EMIS ) is somewhat of an enigma in the biotech world. EMIS is a small biotech/pharmaceutical company that is working on world-changing carrier technologies that allow oral delivery of sensitive therapeutic ingredients. It's been around for a while. EMIS has spent half a billion d...
Source: SeekingAlpha
Date: November, 29 2017 09:21


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EMIS.

About Emisphere Technologies, Inc. (OTC: EMIS)

Logo for Emisphere Technologies, Inc. (OTC: EMIS)

Emisphere is a specialty pharmaceutical company that has recently commenced commercial operations. The Company launched its first prescription product, oral Eligen B , in the U.S. in March . Beyond Eligen B , the Company utilizes its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere is currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit


Contact Information



Current Management

  • Alan L. Rubino / CEO, President
  • Alan Gallantar / Interim CFO
  • Phil Nikolayuk / Finance Manager
  • Tim Rothwell / Chairman
  • John Harkey /
  • Timothy McInerney /
  • Jacob M. Plotsker /
  • Mark Rachescky /
  • Alan L. Rubino /
  • Michael Weiser /

Current Share Structure

  • Market Cap: $20,790,249 - 03/15/2018
  • Authorized: 400,000,000 - 06/13/2016
  • Issue and Outstanding: 60,852,478 - 05/01/2017
  • Float: 46,144,726 - 06/13/2016


Daily Technical Chart for (OTC: EMIS)

Daily Technical Chart for (OTC: EMIS)

Stay tuned for daily updates and more on (OTC: EMIS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: EMIS)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EMIS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EMIS and does not buy, sell, or trade any shares of EMIS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: